文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

摩尔浓度乳酸钠减轻心脏骤停后综合征严重程度:一项临床前研究

Molar Sodium Lactate Attenuates the Severity of Postcardiac Arrest Syndrome: A Preclinical Study.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论兔心脏骤停模型中,再灌注期间持续输注摩尔浓度乳酸钠改善瞳孔对光反射、降低S100β并改善血流动力学,但生存率无差异。

主要终点瞳孔对光反射在乳酸钠组比例更高(83% vs 25%,p=0.01),S100β水平更低(189±42 vs 412±63 pg/mL,p<0.01),并改善氧化磷酸化、线粒体钙保留能力及血流动力学。120分钟再灌注时生存率两组无显著差异(10/12 vs 9/12,p>0.99)。结论提示摩尔浓度乳酸钠可减轻心脏骤停后综合征严重程度,为临床前新视角。

要点

  • 在12.5分钟窒息性心脏骤停兔模型中,再灌注期间持续输注摩尔浓度乳酸钠5 mL/kg/hr使瞳孔对光反射恢复比例达83%,对照组仅25%(p=0.01)。
  • 摩尔浓度乳酸钠组S100β蛋白水平显著低于对照组(189±42 vs 412±63 pg/mL,p<0.01),提示脑损伤减轻。
  • 120分钟再灌注时两组生存率无显著差异(83% vs 75%,p>0.99),但乳酸钠组平均动脉压、心输出量、左室缩短分数更高,左室舒张末压更低(均p<0.05)。
  • 摩尔浓度乳酸钠改善心脏骤停后脑线粒体氧化磷酸化及钙保留能力,并减少液体正平衡(1±3 vs 11±1 mL/kg,p<0.01)。
  • 该证据来自临床前动物实验,不能直接转化为临床推荐剂量或适应症。

适用人群与场景

  • 成年雄性新西兰白兔,经历12.5分钟窒息性心脏骤停并成功复苏后进入120分钟再灌注期。
  • 原文未提及人类急诊或ICU适用人群、纳入或排除标准。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 在再灌注全程120分钟内持续静脉输注摩尔浓度乳酸钠,速率5 mL/kg/hr;对照组输注等量生理盐水。
  • 原文未提及给药途径的具体描述(仅称continuous IV infusion)、频次调整、目标值或人类剂量推荐。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 主要终点瞳孔对光反射:乳酸钠组83% vs 对照组25%(p=0.01)。
  • 关键次要终点:S100β蛋白189±42 vs 412±63 pg/mL(p<0.01);120分钟生存率10/12(83%)vs 9/12(75%),p>0.99。
  • 血流动力学:平均动脉压49±2 vs 29±3 mm Hg、心输出量108±4 vs 58±9 mL/min、左室缩短分数38%±3% vs 19%±3%(均p<0.05),左室舒张末压3±1 vs 8±2 mm Hg(p<0.01)。
  • 液体平衡:对照组11±1 mL/kg vs 乳酸钠组1±3 mL/kg(p<0.01),因对照组利尿减少。

证据类型、等级与局限

  • 证据类型:临床前随机盲法动物实验(兔模型)。

对床旁实践的改变

  • 该临床前结果提示摩尔浓度乳酸钠可能减轻心脏骤停后脑损伤和心血管衰竭,但尚不能改变急诊或ICU对心脏骤停后患者的常规实践。
  • 适用人群仅限该动物模型中的成年雄性新西兰白兔,不适用于人类患者;原文未提及人类适用或不适用人群。
  • 常见陷阱:不能将动物实验中的5 mL/kg/hr输注方案当作人类推荐剂量,也不能将瞳孔对光反射或S100β的改善视为临床结局获益。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether continuous IV infusion of molar sodium lactate would limit cardiac arrest-induced neurologic injury and cardiovascular failure.

DESIGN: Randomized blinded study (animal model).

SETTING: University animal research facility.

SUBJECTS: Twenty-four adult male "New Zealand White" rabbits.

INTERVENTIONS: Anesthetized rabbits underwent 12.5 minutes of asphyxial cardiac arrest and were randomized to receive either normal saline (control group, n = 12) or molar sodium lactate (molar sodium lactate group, n = 12) at a rate of 5 mL/kg/hr during the whole 120-minute reperfusion period.

MEASUREMENTS AND MAIN RESULTS: Pupillary reactivity (primary outcome), levels of S100β protein, in vitro brain mitochondria functions, cardiovascular function, and fluid balance were assessed. Molar sodium lactate reduced brain injury, with a higher proportion of animals exhibiting pupillary reactivity to light (83% vs 25% in the CTRL group, p = 0.01) and lower S100β protein levels (189 ± 42 vs 412 ± 63 pg/mL, p < 0.01) at the end of the protocol. Molar sodium lactate significantly prevented cardiac arrest-induced decrease in oxidative phosphorylation and mitochondrial calcium-retention capacity compared with controls. At 120 minutes of reperfusion, survival did not significantly differ between the groups (10/12, 83% in the molar sodium lactate group vs nine of 12, 75% in the control group; p > 0.99), but hemodynamics were significantly improved in the molar sodium lactate group compared with the control group (higher mean arterial pressure [49 ± 2 vs 29 ± 3 mm Hg; p < 0.05], higher cardiac output [108 ± 4 vs 58 ± 9 mL/min; p < 0.05], higher left ventricle surface shortening fraction [38% ± 3% vs 19% ± 3%; p < 0.05], and lower left ventricular end-diastolic pressure [3 ± 1 vs 8 ± 2 mm Hg; p < 0.01]). While fluid intake was similar in both groups, fluid balance was higher in control animals (11 ± 1 mL/kg) than that in molar sodium lactate-treated rabbits (1 ± 3 mL/kg; p < 0.01) due to lower diuresis.

CONCLUSIONS: Molar sodium lactate was effective in limiting the severity of the postcardiac arrest syndrome. This preclinical study opens up new perspectives for the treatment of cardiac arrest.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Stevic N, Argaud L, Loufouat J, et al. Molar Sodium Lactate Attenuates the Severity of Postcardiac Arrest Syndrome: A Preclinical Study. Crit Care Med. 2022. PMID: 34473656. doi:10.1097/CCM.0000000000005233

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。